ATE405576T1 - Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände - Google Patents

Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände

Info

Publication number: ATE405576T1
Authority: AT; Austria
Prior art keywords: compounds; inflammatory; treatment; androstan; alpha
Prior art date: 2005-01-10

Application number

AT06700486T

Other languages

English (en)

Inventor

Keith Biggadike

Deborah Needham

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2008-09-15

2005-01-10 Priority claimed from GB0500406A external-priority patent/GB0500406D0/en

2005-09-14 Priority claimed from GB0518775A external-priority patent/GB0518775D0/en

2006-01-09 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE405576T1 publication Critical patent/ATE405576T1/de

Links

230000002757 inflammatory effect Effects 0.000 title abstract 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 title 1
206010020751 Hypersensitivity Diseases 0.000 title 1
208000026935 allergic disease Diseases 0.000 title 1
230000007815 allergy Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
238000004519 manufacturing process Methods 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010027654 Allergic conditions Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

AT06700486T 2005-01-10 2006-01-09 Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände ATE405576T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0500406A GB0500406D0 (en)	2005-01-10	2005-01-10	Novel compounds
GB0518775A GB0518775D0 (en)	2005-09-14	2005-09-14	Novel compounds

Publications (1)

Publication Number	Publication Date
ATE405576T1 true ATE405576T1 (de)	2008-09-15

Family

ID=36051466

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06700486T ATE405576T1 (de)	2005-01-10	2006-01-09	Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände

Country Status (7)

Country	Link
US (1)	US20090124588A1 (de)
EP (1)	EP1836215B1 (de)
JP (1)	JP2008526807A (de)
AT (1)	ATE405576T1 (de)
DE (1)	DE602006002366D1 (de)
ES (1)	ES2312104T3 (de)
WO (1)	WO2006072600A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1841780B1 (de) *	2005-01-10	2011-07-27	Glaxo Group Limited	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0523251D0 (en) *	2005-11-15	2005-12-21	Glaxo Group Ltd	Novel compounds
KR20090003349A (ko)	2006-04-20	2009-01-09	글락소 그룹 리미티드	화합물
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
CN102137858B (zh)	2008-05-23	2014-07-23	潘米拉制药有限责任公司	5-脂氧合酶-活化蛋白抑制剂
JP5502858B2 (ja)	2008-06-05	2014-05-28	グラクソグループリミテッド	Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
EP2406255B1 (de)	2009-03-09	2015-04-29	Glaxo Group Limited	4-oxadiazol-2-ylindazole als inhibitoren von pi3-kinasen
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en)	2009-03-17	2010-09-23	Glaxo Group Limited	Pyrimidine derivatives used as itk inhibitors
WO2010107957A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107958A1 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2755773A1 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
JP2012520683A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
MX2011010072A (es)	2009-03-27	2011-10-06	Merck Sharp & Dohme	Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
EP2411520A2 (de)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
WO2010111471A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120010272A1 (en)	2009-03-27	2012-01-12	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012524755A (ja)	2009-04-24	2012-10-18	グラクソグループリミテッド	Ｃｒａｃチャネル阻害剤としてのｎ−ピラゾリルカルボキサミド
EP2421834A1 (de)	2009-04-24	2012-02-29	Glaxo Group Limited	Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals
AR076435A1 (es)	2009-04-30	2011-06-08	Glaxo Group Ltd	Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
WO2011067365A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Benzpyrazole derivatives as inhibitors of p13 kinases
JP2013512880A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
JP2013512878A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	新規化合物
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
RS54286B1 (sr)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
JP5876051B2 (ja)	2010-09-08	2016-03-02	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
WO2012052459A1 (en)	2010-10-21	2012-04-26	Glaxo Group Limited	Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2630126B1 (de)	2010-10-21	2015-01-07	Glaxo Group Limited	Pyrazolverbindungen gegen allergie-, immun- und entzündungserkrankungen
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
EP2683716A1 (de)	2011-03-11	2014-01-15	Glaxo Group Limited	Pyrido[3,4-b]pyrazinderivate als syk-hemmer
JP2016537327A (ja)	2013-10-17	2016-12-01	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
RU2016112266A (ru)	2013-10-17	2017-11-20	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Ингибитор PI3K для лечения респираторного заболевания
WO2015173701A2 (en)	2014-05-12	2015-11-19	Glaxosmithkline Intellectual Property (No. 2) Limited	Pharmaceutical compositions for treating infectious diseases
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
JP2019524792A (ja)	2016-08-08	2019-09-05	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	化合物
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
BR112022019245A2 (pt)	2020-03-26	2022-11-16	Glaxosmithkline Ip Dev Ltd	Inibidores de catepsina para prevenir ou tratar infecções virais

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1438940A (en) *	1972-07-19	1976-06-09	Glaxo Lab Ltd	17beta-haloalkoxycarbonyl-17alpha-oxysteroids
US4996335A (en) *	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
HU225869B1 (en) *	1992-04-02	2007-11-28	Smithkline Beecham Corp	Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US6172054B1 (en) *	1995-06-15	2001-01-09	Alcon Laboratories, Inc.	Combination therapy for lowering and controlling intraocular pressure
US6245804B1 (en) *	1997-05-30	2001-06-12	Schering Aktiengesellschaft	Nonsteroidal gestagens
JP4219554B2 (ja) *	1997-10-01	2009-02-04	協和発酵キリン株式会社	ベンゾフラン誘導体
US6897224B2 (en) *	2002-04-02	2005-05-24	Schering Ag	Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
GB0316290D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
EP1841780B1 (de) *	2005-01-10	2011-07-27	Glaxo Group Limited	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände

2006
- 2006-01-01 US US11/813,230 patent/US20090124588A1/en not_active Abandoned
- 2006-01-09 EP EP06700486A patent/EP1836215B1/de not_active Expired - Lifetime
- 2006-01-09 JP JP2007549870A patent/JP2008526807A/ja not_active Withdrawn
- 2006-01-09 DE DE602006002366T patent/DE602006002366D1/de not_active Expired - Lifetime
- 2006-01-09 AT AT06700486T patent/ATE405576T1/de not_active IP Right Cessation
- 2006-01-09 ES ES06700486T patent/ES2312104T3/es not_active Expired - Lifetime
- 2006-01-09 WO PCT/EP2006/000150 patent/WO2006072600A1/en not_active Ceased

Also Published As

Publication number	Publication date
DE602006002366D1 (de)	2008-10-02
EP1836215B1 (de)	2008-08-20
US20090124588A1 (en)	2009-05-14
WO2006072600A1 (en)	2006-07-13
ES2312104T3 (es)	2009-02-16
JP2008526807A (ja)	2008-07-24
WO2006072600A8 (en)	2007-08-09
EP1836215A1 (de)	2007-09-26

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602006002366D1 (de)	2008-10-02	Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände
GB0418045D0 (en)	2004-09-15	Compounds
ATE517908T1 (de)	2011-08-15	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
NO20084005L (no)	2008-09-19	Aminderivater
MY143390A (en)	2011-05-13	Sulfonamide derivatives for the treatment of diseases.
MX2009006921A (es)	2009-07-06	Derivados azaespiro.
WO2004080964A8 (en)	2005-12-01	Indole derivatives useful for the treatment of diseases
TW200505862A (en)	2005-02-16	2-amino-pyridine derivatives useful for the treatment of diseases
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MX2009007411A (es)	2009-07-17	Derivados de espiropiperidina-glicinamida.
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
TW200505865A (en)	2005-02-16	Compounds useful for the treatment of diseases
ATE454380T1 (de)	2010-01-15	Organische verbindungen zur behandlung entzündlicher oder allergischer leiden
ATE432278T1 (de)	2009-06-15	Verbindungen zur behandlung von krankheiten
MX2009005507A (es)	2009-06-03	Derivados de espiro-piperidina.
DE602007011975D1 (de)	2011-02-24	Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
WO2008077810A3 (en)	2008-09-25	Spiro-piperidine derivatives
TW200833696A (en)	2008-08-16	Spiro-piperidine derivatives
BRPI0508927A (pt)	2007-08-14	compostos úteis para o tratamento de doenças
ATE530552T1 (de)	2011-11-15	Pyrrolobenzimidazolone und deren verwendung als antiproliferative mittel
NO20092413L (no)	2009-07-20	Pyrazolanaloger
NO330964B1 (no)	2011-08-29	Kolkisosidanaloger
TW200728281A (en)	2007-08-01	Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
MX2009006920A (es)	2009-07-06	Indoles.